Citigroup’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-35,000
| Closed | -$674K | – | 6455 |
|
|
2025
Q3 | $674K | Buy |
35,000
+17,500
| +100% | +$312K | ﹤0.01% | 3412 |
|
|
2025
Q2 | $299K | Hold |
17,500
| – | – | ﹤0.01% | 3879 |
|
|
2025
Q1 | $1.12M | Sell |
17,500
-2,500
| -13% | -$263K | ﹤0.01% | 3167 |
|
|
2024
Q4 | $2.43M | Sell |
20,000
-38,900
| -66% | -$4.77M | ﹤0.01% | 2650 |
|
|
2024
Q3 | $7.36M | Buy |
58,900
+3,900
| +7% | +$539K | ﹤0.01% | 1532 |
|
|
2024
Q2 | $8.69M | Buy |
+55,000
| New | +$7.07M | 0.01% | 1326 |
|
|
2024
Q1 | – | Sell |
-25,000
| Closed | -$2.41M | – | 5847 |
|
|
2023
Q4 | $2.41M | Sell |
25,000
-5,000
| -17% | -$480K | ﹤0.01% | 2080 |
|
|
2023
Q3 | $3.64M | Buy |
30,000
+20,000
| +200% | +$2.26M | ﹤0.01% | 1600 |
|
|
2023
Q2 | $1.15M | Sell |
10,000
-16,400
| -62% | -$2.11M | ﹤0.01% | 2742 |
|
|
2023
Q1 | $3.64M | Buy |
26,400
+21,400
| +428% | +$2.78M | ﹤0.01% | 1662 |
|
|
2022
Q4 | $648K | Sell |
5,000
-28,700
| -85% | -$3.33M | ﹤0.01% | 2984 |
|
|
2022
Q3 | $3.73M | Buy |
+33,700
| New | +$3.4M | ﹤0.01% | 1718 |
|
|
2021
Q1 | – | Sell |
-68,000
| Closed | -$11.6M | – | 7293 |
|
|
2020
Q4 | $11.6M | Sell |
68,000
-2,800
| -4% | -$415K | 0.01% | 1436 |
|
|
2020
Q3 | $9.94M | Sell |
70,800
-39,400
| -36% | -$5.99M | 0.01% | 1384 |
|
|
2020
Q2 | $17.7M | Sell |
110,200
-17,700
| -14% | -$2.41M | 0.01% | 899 |
|
|
2020
Q1 | $12.5M | Sell |
127,900
-42,000
| -25% | -$4.8M | 0.01% | 1011 |
|
|
2019
Q4 | $21.9M | Buy |
169,900
+42,200
| +33% | +$4.26M | 0.02% | 913 |
|
|
2019
Q3 | $9.62M | Buy |
127,700
+23,500
| +23% | +$2.78M | 0.01% | 1433 |
|
|
2019
Q2 | $15.8M | Buy |
104,200
+3,700
| +4% | +$450K | 0.01% | 1073 |
|
|
2019
Q1 | $12M | Buy |
100,500
+65,600
| +188% | +$8.43M | 0.01% | 1150 |
|
|
2018
Q4 | $3.81M | Buy |
34,900
+13,600
| +64% | +$1.7M | ﹤0.01% | 2068 |
|
|
2018
Q3 | $3.44M | Sell |
21,300
-19,000
| -47% | -$2.6M | ﹤0.01% | 2220 |
|
|
2018
Q2 | $5.33M | Buy |
40,300
+27,400
| +212% | +$2.58M | ﹤0.01% | 1780 |
|
|
2018
Q1 | $956K | Sell |
12,900
-12,800
| -50% | -$854K | ﹤0.01% | 3288 |
|
|
2017
Q4 | $1.43M | Sell |
25,700
-33,600
| -57% | -$1.78M | ﹤0.01% | 2978 |
|
|
2017
Q3 | $2.69M | Buy |
59,300
+15,700
| +36% | +$627K | ﹤0.01% | 2354 |
|
|
2017
Q2 | $1.47M | Buy |
43,600
+22,000
| +102% | +$716K | ﹤0.01% | 2911 |
|
|
2017
Q1 | $639K | Sell |
21,600
-72,400
| -77% | -$2.24M | ﹤0.01% | 3653 |
|
|
2016
Q4 | $2.58M | Buy |
94,000
+15,800
| +20% | +$635K | ﹤0.01% | 2632 |
|
|
2016
Q3 | $4.8M | Buy |
78,200
+53,000
| +210% | +$1.6M | ﹤0.01% | 1705 |
|
|
2016
Q2 | $481K | Sell |
25,200
-13,400
| -35% | -$248K | ﹤0.01% | 3705 |
|
|
2016
Q1 | $753K | Sell |
38,600
-13,200
| -25% | -$231K | ﹤0.01% | 3670 |
|
|
2015
Q4 | $2M | Buy |
51,800
+19,600
| +61% | +$636K | ﹤0.01% | 2485 |
|
|
2015
Q3 | $1.03M | Sell |
32,200
-21,000
| -39% | -$713K | ﹤0.01% | 3057 |
|
|
2015
Q2 | $1.62M | Buy |
53,200
+38,300
| +257% | +$783K | ﹤0.01% | 2740 |
|
|
2015
Q1 | $198K | Buy |
14,900
+14,300
| +2,383% | +$191K | ﹤0.01% | 4532 |
|
|
2014
Q4 | $9K | Buy |
+600
| New | +$10.2K | ﹤0.01% | 6512 |
|
Other funds holding SRPT
VPM
VCM
RCM
EAM
Citigroup's SRPT Position: Q1 2026 in Review
Citigroup increased its Sarepta Therapeutics (SRPT) stake by 0.13% in Q1 2026, buying an estimated $28.5K and bringing the position to 1,147,648 shares worth $25M. The position accounts for 0.01% of the portfolio, ranked #955.
Citigroup first reported a position in SRPT in Q2 2013 and has held it in 52 quarters since. The position peaked at $34.2M in Q2 2019. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.
- Citigroup held 1,147,648 shares of Sarepta Therapeutics worth $25M as of Q1 2026.
- Citigroup bought 1,473 Sarepta Therapeutics shares in Q1 2026, an estimated $28.5K.
- Sarepta Therapeutics made up 0.01% of Citigroup's portfolio in Q1 2026, its #955 holding.
- Citigroup first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 52 quarters since.
- Citigroup's Sarepta Therapeutics position peaked at $34.2M in Q2 2019.
- 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.